William Ho - CEO, IN8bio - Next Generation Cell Therapies For Cancer

William Ho is a Co-Founder, and has served as the President, Chief Executive Officer, and Director of IN8bio ( https://in8bio.com/ ), a biotech company with a mission of developing next-generation therapies for treating cancer, with a focus on gamma-delta T cells, since its inception.

Mr. Ho has worked in the biotechnology industry for nearly 24 years.

Prior to the founding of IN8bio, from 2014 to 2017, Mr. Ho was the Founder and Managing Partner at AlephPoint Capital, a private healthcare investment fund. Prior to that, Mr. Ho was at New Leaf Venture Partners, a leading healthcare venture capital firm, where he launched and managed the public investments and cross-over portfolio and served as its Public Investment Director from 2010 to 2014.

Previously, Mr. Ho served as a Senior Equity Research Analyst at Bank of America from 2006 to 2009 and an Equity Research Analyst at Piper Jaffray & Co. from 2003 to 2006, covering the biotechnology and life-science tools sectors.

Earlier in his career, Mr. Ho was responsible for FP&A and operational analysis at CuraGen Corporation and worked as an Associate on the Healthcare Investment Banking team at Cowen, Inc.

Mr. Ho was an inductee into the McMaster University Alumni Gallery in 2020 and previously served as a member of their Dean’s Advisory Board for the Faculty of Science.

Mr. Ho received an MBA from the University of Notre Dame and a B.S. in Biochemistry from McMaster University.

#WilliamHo #IN8bio #GammaDeltaTCells #ImmuneSystem #Glioblastoma #AcuteMyeloidLeukemia #NonSignalingCART #InducedPluripotentStemCells
#Oncology #Immunooncology #Cancer #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research